Effects of Gasdermin D in Modulating Murine Lupus and its Associated Organ Damage
ObjectiveGasdermin D (GSDMD) is the key executioner of an inflammatory cell death mechanism known as pyroptosis. Recent reports have also implicated GSDMD in other mechanisms of cell death, including apoptosis, necroptosis, and NETosis. Given the role of dysregulated cell death in autoimmune syndromes such as systemic lupus erythematosus (SLE), this study was undertaken in a murine lupus model to investigate whether GSDMD plays a pathogenic role in systemic autoimmunity by promoting inflammatory cell death, leading to increased generation of nuclear autoantigens and autoantibodies.MethodsAn imiquimod ‐induced model of SL...
Source: Arthritis and Rheumatology - October 17, 2020 Category: Rheumatology Authors: Xinghao Wang, Luz P. Blanco, Carmelo Carmona ‐Rivera, Shuichiro Nakabo, Hege L. Pedersen, Zu‐Xi Yu, Mariana J. Kaplan Tags: Full Length Source Type: research

Anti –Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome
ConclusionOur data indicate high levels of anti ‐NET antibodies in patients with primary APS, which may impair NET clearance and activate the complement cascade. These findings may ultimately enable more effective risk stratification. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 16, 2020 Category: Rheumatology Authors: Yu Zuo, Srilakshmi Yalavarthi, Kelsey Gockman, Jacqueline A. Madison, Johann E. Gudjonsson, J. Michelle Kahlenberg, W. Joseph McCune, Paula L. Bockenstedt, David R. Karp, Jason S. Knight Tags: Brief Report Source Type: research

Multimorbidity in Anti ‐Neutrophil Cytoplasmic Antibody‐associated vasculitis: results from a longitudinal, multi‐centre data‐linkage study
ABSTRACTObjectivesANCA ‐associated vasculitis (AAV) is considered a chronic, relapsing condition. To date, no studies have investigated multimorbidity in AAV nationally. Here, we characterise temporal trends in multimorbidity and report excess healthcare expenditure associated with it in a national AAV cohort.MethodsAAV patients diagnosed between 1997 and 2017 were matched with five general population controls. Linked morbidity and healthcare expenditure data were retrieved from a national hospitalisation repository and nationally ‐published cost data. Multimorbidity was defined as the development of ≥2 disorders. P...
Source: Arthritis and Rheumatology - October 15, 2020 Category: Rheumatology Authors: Shifa H Sarica, Peter J Gallacher, Neeraj Dhaun, Jan Sznajd, John Harvie, John McLaren, Lucy McGeoch, Vinod Kumar, Nicole Amft, Lars Erwig, Angharad Marks, Laura Bruno, York Z öllner, Corri Black, Neil Basu Tags: FULL LENGTh Source Type: research

Association of Agricultural, Occupational, and Military Inhalants with Autoantibodies and Disease Features in U.S. Veterans with Rheumatoid Arthritis
ConclusionMilitary burn pit and military waste disposal exposures were independently associated with the presence of anti ‐CCP antibodies in RA patients. These findings are consistent with emerging evidence that various inhalant exposures influence autoantibody expression and RA risk. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 15, 2020 Category: Rheumatology Authors: Ariadne V. Ebel, Gabrielle Lutt, Jill A. Poole, Geoffrey M. Thiele, Joshua F. Baker, Grant W. Cannon, Angelo Gaffo, Gail S. Kerr, Andreas Reimold, Pascale Schwab, Namrata Singh, J. Steuart Richards, Dana P. Ascherman, Ted R. Mikuls, Bryant R Tags: FULL LENGTH Source Type: research

Interleukin ‐7/Interferon axis drives T‐cell and salivary gland epithelial cell interactions in Sjögren’s syndrome
ConclusionThese results suggest an IL ‐7‐IFNγ amplification loop involving SGECs and T cells in pSS. IL‐7 was secreted by SGECs stimulated with type 1 or type 2 IFN and, in turn, activate T cells that secrete type 2 IFN. An anti‐IL‐7R antibody decreased the IFN signature in T cells during pSS and could be of therapeutic inter est. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 15, 2020 Category: Rheumatology Authors: Elodie Rivi ère, Juliette Pascaud, Alexandre Virone, Anastasia Dupré, Bineta Ly, Audrey Paoletti, Raphaèle Seror, Nicolas Tchitchek, Michael Mingueneau, Nikaïa Smith, Darragh Duffy, Lydie Cassard, Nathalie Chaput, Sabrina Pengam, Vanessa Tags: FULL LENGTH Source Type: research

Autoantibodies to Malondialdehyde –Acetaldehyde Are Detected Prior to Rheumatoid Arthritis Diagnosis and After Other Disease Specific Autoantibodies
ObjectiveTo examine serum autoantibodies to malondialdehyde –acetaldehyde (MAA) prior to rheumatoid arthritis (RA) diagnosis.MethodsConcentrations of anti ‐MAA antibody isotypes, anti–cyclic citrullinated peptide 2 (anti–CCP‐2), and IgM rheumatoid factor (IgM‐RF) were evaluated before and after RA diagnosis in samples from cases (n = 214) and controls (n = 210). The timing of elevations in autoantibody concentrations relative to RA diagnosis was explored using separate mixed models for each antibody and/or isotype. Associations between prediagnosis autoantibody concentrations in RA patients were exa...
Source: Arthritis and Rheumatology - October 15, 2020 Category: Rheumatology Authors: Ted R. Mikuls, Jess Edison, Elizabeth Meeshaw, Harlan Sayles, Bryant R. England, Michael J. Duryee, Carlos D. Hunter, Lindsay B. Kelmenson, Laura Kay Moss, Marie L. Feser, Brandie Wagner, Mark C. Parish, Kevin D. Deane, Geoffrey M. Thiele Tags: Brief Report Source Type: research

Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVID ‐19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect?
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 15, 2020 Category: Rheumatology Authors: Pierre Miossec Tags: Editorial Source Type: research

Efficacy and Safety of Guselkumab, an Interleukin ‐23p19‐Specific Monoclonal Antibody, Through 1 Year in Biologic‐naïve Psoriatic Arthritis Patients
ConclusionIn biologic ‐naïve PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable benefit‐risk profile through Week52. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 11, 2020 Category: Rheumatology Authors: Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Xie L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, Shihong Sheng, Yusang Jiang, Bei Zhou, Yanli Zhuang, D ésirée van, der Heijde, Phili Tags: FULL LENGTH Source Type: research

Persistent Bacteriuria and Antibodies Recognizing Curli/eDNA Complexes From Escherichia coli Are Linked to Flares in Systemic Lupus Erythematosus
ConclusionThese results suggest that UTIs and persistent bacteriuria are environmental triggers of lupus and its flares. Antibodies against curli/eDNA could serve as a sign of systemic exposure to bacterial products in SLE. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 11, 2020 Category: Rheumatology Authors: Ryan J. Pachucki, Chelsea Corradetti, Lynne Kohler, Jay Ghadiali, Paul M. Gallo, Lauren Nicastro, Sarah A. Tursi, Stefania Gallucci, Çagla Tükel, Roberto Caricchio Tags: Original Article Source Type: research

Do hydroxychloroquine blood levels and dose identify different populations at risk of retinopathy? Comment on the article by Petri et al
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 11, 2020 Category: Rheumatology Authors: Michael R. Bubb Tags: Letters Source Type: research

Efficacy and Safety of E6011, an Anti ‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study
ConclusionThis is the first evidence that E6011, a novel cell trafficking inhibitor targeting the FKN ‐CX3CR1 interaction, is modestly effective at 24 weeks treatment in RA patients, although the primary endpoint was not met. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 10, 2020 Category: Rheumatology Authors: Yoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, Toshihiro Nanki, Hisanori Umehara, Nobuyuki Yasuda, Fumitoshi Tago, Yasumi Kitahara, Makoto Kawakubo, Kentaro Torii, Seiichiro Hojo, Tetsu Kawano, Toshio Imai Tags: Full Length Source Type: research

Distinct expression of coinhibitory molecules on alveolar T cells in patients with rheumatoid arthritis ‐ and idiopathic inflammatory myopathies‐associated interstitial lung disease
AbstractObjectivesTo identify immunologic factors in lungs of patients with rheumatoid arthritis ‐associated interstitial lung disease (RA‐ILD) and idiopathic inflammatory myopathies‐associated ILD (IIM‐ILD) and to examine their pathological mechanisms.MethodsA total of 11 patients with RA ‐ILD, 16 with IIM‐ILD, and 6 with drug‐induced ILD (DI‐ILD) and 8 healthy controls were enrolled. Peripheral blood and bronchoalveolar lavage fluid (BALF) were immunophenotyped by flow cytometry. Alveolar macrophages (AMs) were analyzed by coculture assay with peripheral naïve CD4+ T cells of healthy individuals and ...
Source: Arthritis and Rheumatology - October 10, 2020 Category: Rheumatology Authors: Maho Nakazawa, Katsuya Suzuki, Masaru Takeshita, Jun Inamo, Hirofumi Kamata, Makoto Ishii, Yoshitaka Oyamada, Hisaji Oshima, Tsutomu Takeuchi Tags: FULL LENGTH Source Type: research

MicroRNA ‐34a‐5p Promotes Joint Destruction during Osteoarthritis
AbstractObjectivesMicroRNA ‐34a‐5p (miR‐34a‐5p) expression is elevated in the synovial fluid of late‐stage knee osteoarthritis (OA); however, its exact role and therapeutic potential in OA remains to be fully elucidated.MethodsMiR ‐34a‐5p expression was determined in joint tissues and human plasma (n=71). miR‐34a‐5p mimic or antisense‐oligonucleotide (ASO) treatment experiments were performed in human OA chondrocytes, fibroblast‐like synoviocytes (FLS) (n=7‐9) and mouse OA models including destabilization of the medial meniscus (DMM) (n=22) and the accelerated, more severe model of high‐fat diet (...
Source: Arthritis and Rheumatology - October 8, 2020 Category: Rheumatology Authors: Helal Endisha, Poulami Datta, Anirudh Sharma, Sayaka Nakamura, Evgeny Rossomacha, Carolen Younan, Shabana A. Ali, Ghazaleh Tavallaee, Starlee Lively, Pratibha Potla, Konstantin Shestopaloff, Jason S. Rockel, Roman Krawetz, Nizar N. Mahomed, Tags: FULL LENGTH Source Type: research

Bioactive Plasma Mitochondrial DNA is Associated With Disease Progression in Scleroderma ‐Associated Interstitial Lung Disease
ConclusionThese findings demonstrate a previously unrecognized connection between EV ‐encapsulated mtDNA, clinical outcomes, and intracellular DNA–sensing PRR activation in SSc‐ILD. Further study of these interactions could catalyze novel mechanistic and therapeutic insights into SSc‐ILD and related disorders. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 8, 2020 Category: Rheumatology Authors: Changwan Ryu, Anjali Walia, Vivian Ortiz, Carrighan Perry, Sam Woo, Benjamin C. Reeves, Huanxing Sun, Julia Winkler, Jean E. Kanyo, Weiwei Wang, Milica Vukmirovic, Nicholas Ristic, Eric A. Stratton, Sita Ram Meena, Maksym Minasyan, Daniel K Tags: Full Length Source Type: research

Frequency and results of cryoglobulin retesting in 4,963 patients: comment on the article by Kolopp ‐Sarda et al
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 8, 2020 Category: Rheumatology Authors: Patrizia Natali, Daria Debbia, Tommaso Trenti, Giuliana Galassi, Johanna Chester, Gilda Sandri, Maria T. Mascia Tags: Letters Source Type: research

Trends in Utilization of Urate ‐Lowering Therapies Following the FDA’s Boxed Warning to Febuxostat in the U.S.
AbstractGout is the most common inflammatory arthritis affecting nearly 4% of adults (9.2 millions) in the U.S. Initiation of urate ‐lowering therapy (ULT) is strongly recommended for all patients with tophaceous gout, radiographic damage, or frequent gout flares. While allopurinol is the first‐line ULT, some patients do not tolerate or adequately respond to allopurinol and require a different ULT such as febuxostat. At the time of approval of febuxostat in February 2009, the U.S. Food and Drug Administration (FDA) mandated a post‐marketing cardiovascular safety trial (the CARES trial) to address concerns related to ...
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Seoyoung C Kim, Tuhina Neogi, Erin Kim, Joyce Lii, Rishi J Desai Tags: LETTER TO THE EDITOR Source Type: research

Pulmonary Adverse Events in Patients Receiving Low ‐Dose Methotrexate in the Randomized, Double‐Blind, Placebo‐Controlled Cardiovascular Inflammation Reduction Trial
We described severe pulmonary AEs an d examined associations of baseline characteristics with pulmonary AEs in patients receiving low‐dose MTX.ResultsA total of 2,391 subjects were randomized to receive low ‐dose MTX and 2,395 to receive placebo. There were 13 severe pulmonary AEs (0.5%) and 7 cases of possible pneumonitis (0.3%) in the low‐dose MTX group, compared to 8 (0.3%) and 1 (
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Jeffrey A. Sparks, Paul F. Dellaripa, Robert J. Glynn, Nina P. Paynter, Chang Xu, Paul M. Ridker, Daniel H. Solomon Tags: Brief Report Source Type: research

Reply
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Marcela A. Ferrada, Peter C. Grayson Tags: Letters Source Type: research

DNA Methylation and Brain ‐Derived Neurotrophic Factor Expression Account for Symptoms and Widespread Hyperalgesia in Patients With Chronic Fatigue Syndrome and Comorbid Fibromyalgia
ConclusionOur findings indicate that sBDNF levels are elevated in patients with CFS/FM and that BDNF methylation in exon 9 accounts for the regulation of protein expression. Altered BDNF levels might represent a key mechanism explaining CFS/FM pathophysiology. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Andrea Polli, Manosij Ghosh, Jelena Bakusic, Kelly Ickmans, Dora Monteyne, Brigitte Velkeniers, Bram Bekaert, Lode Godderis, Jo Nijs Tags: Full Length Source Type: research

Antiphospholipid Antibodies in Critically Ill Patients With COVID ‐19
ConclusionAntiphospholipid antibodies were common in critically ill patients with COVID ‐19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetica lly predisposed patients, COVID‐19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as “COVID‐19–induced APS‐like syndrome.” Long‐term follow‐up of...
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Meng Xiao, Yan Zhang, Shulan Zhang, Xuzhen Qin, Peng Xia, Wei Cao, Wei Jiang, Huan Chen, Xin Ding, Hua Zhao, Hongmin Zhang, Chunyao Wang, Jing Zhao, Xuefeng Sun, Ran Tian, Wei Wu, Dong Wu, Jie Ma, Yu Chen, Dong Zhang, Jing Xie, Xiaowe Tags: Brief Report Source Type: research

Granulomatosis with Polyangiitis Sustained Remission Off ‐Therapy: Data from the French Vasculitis Study Group Registry
AbstarctObjectiveData on granulomatosis with polyangiitis (GPA) sustained remission off ‐therapy (SROT, never relapsed) are scarce. SROT in GPA patients from the French Vasculitis Study Group Registry was evaluated to identify factors associated with its occurrence and durability.MethodsGPA had to satisfy ACR criteria and/or the Chapel Hill Nomenclature for study inclusion. SROT was defined as remission (BVAS=0) without glucocorticoids (GC) or immunosuppressants (IS) for ≥6 consecutive months. Patients’ baseline characteristics and treatments at 3, 5 and 10 years were compared according to achieved/maintained SR...
Source: Arthritis and Rheumatology - October 7, 2020 Category: Rheumatology Authors: Xavier Pu échal, Michele Iudici, Christian Pagnoux, Alexandre Karras, Pascal Cohen, François Maurier, Thomas Quéméneur, François Lifermann, Mohamed Hamidou, Luc Mouthon, Benjamin Terrier, Loïc Guillevin, The French Vasculitis Study Group Tags: FULL LENGTH Source Type: research

Mechanosensitive Control of Articular Cartilage and Subchondral Bone Homeostasis Requires Osteocytic TGF β Signaling
ConclusionOur results provide new evidence that osteocytic TGF β signaling is required for a mechanosensitive response to injury, and that osteocytes control SBP homeostasis to maintain cartilage health, uncovering osteocytic TGFβ signaling as a novel therapeutic target for OA. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 6, 2020 Category: Rheumatology Authors: Karsyn N. Bailey, Jeffrey Nguyen, Cristal S. Yee, Neha S. Dole, Alexis Dang, Tamara Alliston Tags: FULL LENGTH Source Type: research

JNK pathway as a target for osteoarthritis: comment on the article by Loeser et al
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 5, 2020 Category: Rheumatology Authors: Wang ‐Dong Xu, An‐Fang Huang Tags: Letters Source Type: research

Sequence ‐based screening of patients with idiopathic polyarteritis nodosa, granulomatosis with polyangiitis, and microscopic polyangiitis for deleterious genetic variants in ADA2
ConclusionA subset of patients with idiopathic PAN meet genetic criteria for DADA2. Given that TNF ‐inhibition is efficacious in DADA2 but is not conventional therapy for PAN, these findings suggest that ADA2 testing should strongly be considered in patients with HBV‐negative idiopathic PAN. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 5, 2020 Category: Rheumatology Authors: Oskar Schnappauf, Natalia Sampaio Moura, Ivona Aksentijevich, Monique Stoffels, Amanda K. Ombrello, Patrycja Hoffmann, Karyl Barron, Elaine F. Remmers, Michael Hershfield, Susan J. Kelly, NISC Comparative Sequencing Program, David Cuthbertson, Tags: BRIEF REPORT Source Type: research

Clinical Images: IgG4 ‐related orbital pseudotumor
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 4, 2020 Category: Rheumatology Authors: Wen ‐Chi Wu, Hsien‐Tzung Liao Tags: Clinical Image Source Type: research

Reply
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 2, 2020 Category: Rheumatology Authors: Paras Karmacharya, Ali Duarte-Garcia, M. Hassan Murad, Maureen Dubreuil, Ravi Shahukhal, Pragya Shrestha, Elena Myasoedova, Cynthia S. Crowson, Kerry Wright, John M. Davis Tags: Letters Source Type: research

Latent Class Growth Analysis of Gout Flare Trajectories: A  Three‐Year Prospective Cohort Study in Primary Care
ObjectiveTo investigate the existence of distinct classes of gout flare trajectories and compare their gout ‐specific, comorbid, and sociodemographic characteristics.MethodsIn a prospective cohort study, adults with gout who were registered with 20 general practices self ‐reported the number of gout flares experienced at baseline and after 6, 12, 24, and 36 months via postal questionnaires. Latent class growth analysis (LCGA) was used to identify distinct gout flare trajectory classes. Statistical criteria and clinical interpretability were used to decide the opti mal number of classes. Baseline comorbidities, medicati...
Source: Arthritis and Rheumatology - October 2, 2020 Category: Rheumatology Authors: Lorraine Watson, John Belcher, Elaine Nicholls, Sara Muller, Christian Mallen, Edward Roddy Tags: Full Length Source Type: research

Reduction in Osteoarthritis Risk After Treatment With Ticagrelor Compared to Clopidogrel: A Propensity Score –Matching Analysis
This study was undertaken to determine whether treatment with ticagrelor was associated with a lower risk of OA.MethodsWe conducted a 1:2 propensity score –matching analysis using data from 2011–2017 in the Optum Clinformatics Data Mart. Patients who had received either ticagrelor or clopidogrel for ≥90 days were included in our study, and patients with a prior diagnosis of OA or inflammatory arthritis were excluded. OA was identified using Inte rnational Classification of Diseases codes. The primary outcome was the time to diagnosis of OA after treatment with ticagrelor versus clopidogrel.ResultsOur propens...
Source: Arthritis and Rheumatology - October 2, 2020 Category: Rheumatology Authors: Matthew C. Baker, Yingjie Weng, William H. Robinson, Neera Ahuja, Nidhi Rohatgi Tags: Full Length Source Type: research

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS –CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
ConclusionOur understanding of SARS –CoV‐2–related syndromes in the pediatric population continues to evolve. The guidance provided in this “living document” reflects currently available evidence, coupled with expert opinion, and will be revised as further evidence becomes available. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 2, 2020 Category: Rheumatology Authors: Lauren A. Henderson, Scott W. Canna, Kevin G. Friedman, Mark Gorelik, Sivia K. Lapidus, Hamid Bassiri, Edward M. Behrens, Anne Ferris, Kate F. Kernan, Grant S. Schulert, Philip Seo, Mary Beth F. Son, Adriana H. Tremoulet, Rae S. M. Yeung, Am Tags: Full Length Source Type: research

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels
ConclusionsThese data indicate an important role of IL ‐12 blockade in the mechanism of action of ustekinumab in SLE. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - October 2, 2020 Category: Rheumatology Authors: Matteo Cesaroni, Loqmane Seridi, Matthew J. Loza, Jessica Schreiter, Kristen Sweet, Carol Franks, Keying Ma, Ashley Orillion, Kim Campbell, Robert Gordon, Patrick Branigan, Peter Lipsky, Ronald van Vollenhoven, Bevra H. Hahn, George C. Tsoko Tags: BRIEF REPORT Source Type: research

Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma
AbstractObjectivesIntravenous iloprost improves Raynaud ‘s phenomenon (RP) and promotes healing of digital ulcers (DU) in scleroderma (SSc). Despite a short half‐life, its clinical efficacy lasts weeks. Endothelial adherens junctions, which are formed by VE‐cadherin clustering between endothelial cells (ECs), regulate endothelial properties includi ng barrier function, endothelial to mesenchymal transition (Endo‐MT), and angiogenesis. We hypothesized that junctional disruption contributes to vascular dysfunction in SSc, and that the protective effect of iloprost is mediated by strengthening of those junctions.M...
Source: Arthritis and Rheumatology - September 30, 2020 Category: Rheumatology Authors: Pei ‐Suen Tsou, Pamela J. Palisoc, Nicholas A. Flavahan, Dinesh Khanna Tags: FULL LENGTH Source Type: research

Serum oxylipins profiling during the earliest stages of rheumatoid arthritis
Conclusionoxylipins networks differ across stages during earliest phases of RA. Oxylipins can inform on pathways with clinical relevance for disease progression, clinical heterogeneity and treatment response. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 30, 2020 Category: Rheumatology Authors: Javier Rodr íguez‐Carrio, Roxana Coras, Mercedes Alperi‐López, Patricia López, Catalina Ulloa, Francisco Javier Ballina‐García, Aaron M Armando, Oswald Quehenberger, Mónica Guma, Ana Suárez Tags: FULL LENGTH Source Type: research

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis: data from a European Collaborative Study
ConclusionThese results suggest that rituximab could be effective in EGPA vasculitis relapses. Mepolizumab is highly effective with a good safety profile in GC ‐dependent asthma. Our data suggest that 100 mg monthly could be an acceptable first‐line dose in selected instances of EGPA recognizing though that this has not been compared to the validated dose of 300 mg monthly. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 30, 2020 Category: Rheumatology Authors: Alice Canzian, Nils Venhoff, Maria Letizia Urban, Silvia Sartorelli, Anne ‐Marie Ruppert, Matthieu Groh, Nicolas Girszyn, Camille Taillé, François Maurier, Vincent Cottin, Claire de Moreuil, Vincent Germain, Maxime Samson, Marie Jachiet, Tags: BRIEF REPORT Source Type: research

Allele ‐specific quantification of HLA‐DRB1 transcripts reveals imbalanced allelic expression that modifies the amino acid effects in HLA‐DRβ1
ConclusionOur finding illustrates the advantage of integrating quantitative and qualitative changes inHLA ‐DRB1 into a single model for understandingHLA ‐DRB1 associations. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 30, 2020 Category: Rheumatology Authors: Sehwan Chun, So ‐Young Bang, Eunji Ha, Jing Cui, Ki‐Nam Gu, Hye‐Soon Lee, Kwangwoo Kim, Sang‐Cheol Bae Tags: FULL LENGTH Source Type: research

Reply
Arthritis& Rheumatology, EarlyView. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 29, 2020 Category: Rheumatology Authors: Richard F. Loeser, John A. Collins, Brian O. Diekman, Cathy S. Carlson Tags: Letters Source Type: research

Expert Perspective: An Evidence ‐Based Approach to Refractory Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease that can present with a variety of skin manifestations and have a dramatic effect on a patient ’s quality of life. Effective treatment options for this disease are limited, and the efficacy of these treatments is often supported by low levels of evidence. This makes the treatment of refractory disease especially challenging, as it is difficult to achieve a consensus on the appropriate progr ession of treatment beyond first‐ and second‐line treatment options. The treatment of refractory CLE often involves some degree of immunosuppression, which ca...
Source: Arthritis and Rheumatology - September 29, 2020 Category: Rheumatology Authors: Robert Borucki, Victoria P. Werth Tags: EXPERT PERSPECTIVES ON CLINICAL CHALLENGES Source Type: research

The β2‐Glycoprotein I/HLA–DR Complex As A Major Autoantibody Target in Obstetric Antiphospholipid Syndrome
ConclusionThe anti ‐β2GPI/HLA –DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings may provide potential new therapeutic strategies for addressing RPL in patients with obstetric APS. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 29, 2020 Category: Rheumatology Authors: Kenji Tanimura, Shigeru Saito, Mikiya Nakatsuka, Takeshi Nagamatsu, Tomoyuki Fujii, Atsushi Fukui, Masashi Deguchi, Yuki Sasagawa, Noriko Arase, Hisashi Arase, Hideto Yamada Tags: Full Length Source Type: research

Association of Anti –Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
This study was u ndertaken to gain insight into the association between characteristics of the anti–topo I antibody response and clinical disease course in SSc patients positive for anti–topo I antibodies.MethodsLevels of anti –topo I IgG, anti–topo I IgM, and anti–topo I IgA were assessed in consecutive serum samples obtained from patients at baseline who were positive for anti–topo I IgG in the Leiden Combined Care In Systemic Sclerosis (CCISS) cohort. One‐year disease progression was defined by a relevant inc rease in modified Rodnan skin thickness score (MRSS), decline in pulmonary...
Source: Arthritis and Rheumatology - September 28, 2020 Category: Rheumatology Authors: Maaike Boonstra, Jaap A. Bakker, Annette Grummels, Maarten K. Ninaber, Nina Ajmone Marsan, Corrie M. Wortel, Tom W. J. Huizinga, Suzana Jordan, Anna ‐Maria Hoffman‐Vold, Oliver Distler, René E. M. Toes, Hans Ulrich Scherer, Jeska K. Vries Tags: Original Article Source Type: research

American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID ‐19 Pandemic: Version 1
ConclusionThese guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS –CoV‐2 infection. This guidance is presented as a “living document,” recognizing that the literature on COVID‐19 is rapidly evolving, with future updates anticipated. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 27, 2020 Category: Rheumatology Authors: Dawn M. Wahezi, Mindy S. Lo, Tamar B. Rubinstein, Sarah Ringold, Stacy P. Ardoin, Kevin J. Downes, Karla B. Jones, Ronald M. Laxer, Rebecca Pellet Madan, Amy S. Mudano, Amy S. Turner, David R. Karp, Jay J. Mehta Tags: Full Length Source Type: research

Incorrect Data in Tables and Omission of Author Name in the Article by Bowman et al (Arthritis Rheumatol, July 2017)
Arthritis& Rheumatology, Volume 72, Issue 10, Page 1748-1748, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Tags: Erratum Source Type: research

Journal Club
Arthritis& Rheumatology, Volume 72, Issue 10, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Tags: Journal Club Source Type: research

Issue Information
Arthritis& Rheumatology, Volume 72, Issue 10, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Tags: Issue Information Source Type: research

Clinical Connections
Arthritis& Rheumatology, Volume 72, Issue 10, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Tags: Clinical Connections Source Type: research

In This Issue
Arthritis& Rheumatology, Volume 72, Issue 10, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Tags: In This Issue Source Type: research

Cholesterol and Monosodium Urate Monohydrate Crystals in Synovial fluid From a Patient With Gout
Arthritis& Rheumatology, Volume 72, Issue 10, Page 1706-1706, October 2020. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 25, 2020 Category: Rheumatology Authors: Pankaj Bansal, Andrew R. Virata Tags: Clinical Image Source Type: research

Imaging based uveitis surveillance in juvenile idiopathic arthritis: feasibility, acceptability and diagnostic performance
ConclusionNon ‐contact, high‐resolution imaging for JIA uveitis surveillance is feasible, acceptable to patients, and holds the promise of transforming paediatric practice. Further work is needed to determine the analytic and clinical validity of AS‐OCT quantification of active inflammation, and the clinica l and cost‐effectiveness of imaging based disease monitoring. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 24, 2020 Category: Rheumatology Authors: Saira Akbarali, Jugnoo S Rahi, Andrew D Dick, Kiren Parkash, Katie Etherton, Clive Edelsten, Xiaoxuan Liu, Ameenat L Solebo Tags: BRIEF REPORT Source Type: research

Elucidating Epigenetic Regulation by Identifying Functional cis ‐Acting Long Noncoding RNAs and Their Targets in Osteoarthritic Articular Cartilage
ConclusionBy applying an improved detection strategy, robustly differentially expressed lncRNAs in OA cartilage were detected. Integration of these lncRNAs with differential mRNA expression levels in the same samples provided insight into their regulatory networks. Our data indicates that intergenic and antisense lncRNAs play an important role in regulating the pathophysiology of OA. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 23, 2020 Category: Rheumatology Authors: Marcella Hoolwerff, Paula I. Metselaar, Margo Tuerlings, H. Eka D. Suchiman, Nico Lakenberg, Yolande F.M. Ramos, Davy Cats, Rob G.H.H. Nelissen, Demi ën Broekhuis, Hailiang Mei, Rodrigo Coutinho Almeida, Ingrid Meulenbelt Tags: Full Length Source Type: research

Cardiovascular and renal morbidity in Takayasu arteritis: a population ‐based retrospective cohort study from UK
ConclusionCardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti ‐platelets in these patients was suboptimal. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 22, 2020 Category: Rheumatology Authors: Ruchika Goel, Joht Singh Chandan, Rasiah Thayakaran, Nicola J Adderley, Krishnarajah Nirantharakumar, Lorraine Harper Tags: FULL LENGTH Source Type: research

A novel RELA truncating mutation in familial Beh çet’s Disease‐like mucocutaneous ulcerative condition.
ConclusionsOur data supportRELA loss ‐of‐function mutations as causing BD‐like autoinflammation and NMO via impaired NF‐κB signalling and increased apoptosis. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - September 22, 2020 Category: Rheumatology Authors: Fahd Adeeb, Emma R. Dorris, Niamh E. Morgan, Dylan Lawless, Aqeel Maqsood, Wan Lin Ng, Orla Killeen, Eoin P. Cummins, Cormac T. Taylor, Sinisa Savic, Anthony G. Wilson, Alexander Fraser Tags: BRIEF REPORT Source Type: research